Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac and Metabolic Effects of Dapagliflozin in the Failing Fontan Circulation
NCT06762964Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- May 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in Fontan failure (FF), heart failure with preserved ejection fraction (HFpEF), sponsored by Mayo Clinic. Started May 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Fontan failure (FF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06762964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762964.